On the morning of April 2, BirdoTech held a signing ceremony with Shanghai Lingang Fengxian Economic Development Co., Ltd. (hereinafter referred to as Lingang Fengxian Company). And BirdoTech successfully settled in Lingang area of the Shanghai pilot.
Mr. Wang Lei, chairman of BirdoTech, and Mr. Lv Jun, executive deputy general manager of Lingang Fengxian Company signed the contract on behalf of both parties. Ms. Xue Li, deputy general manager of BirdoTech, Mr. Zou Linkun, secretary of CPC committee of hospital, chairman and general manager of Lingang Fengxian Company, Ms. Qu Xia, deputy general manager, Mr. Zhang Jianyong, general manager assistant, Ms. Pan Xiaoyue and other leaders attended and witnessed the signing of the contract.
BirdoTech is a national high-tech enterprise registered in Shanghai, China. The company adheres to the corporate values of “Integrity, Credibility, Breakthrough, Innovation” takes “Your R&D partner in building a healthier future for all” as the enterprise vision to provide comprehensive and integrated R&D and production services for the global pharmaceutical industry.
The international new drug R&D service platform project invested and constructed in the Lingang area of the Shanghai pilot covers an area of 8,000 square meters. After the operation of the project, it will further enhance the technical strength, optimize the management concepts, improve the service capabilities for company, promote the accelerated integration of overseas innovation and domestic resources and help to improve the position and influence of the Chinese biomedicine industry in the global new drug R&D industrial chain.